Premium
T‐cell precursor frequencies and long‐term outcome following unrelated hematopoietic stem cell transplantation
Author(s) -
KIRCHER B.,
NIEDERWIESER D.,
GÄCHTER A.,
LINDNER B.,
MITTERSCHIFFTHALER A.,
URBAN C.,
GREINIX H.,
PETERS C.,
LÄTZER K.,
GASTL G.,
NACHBAUR D.
Publication year - 2008
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2007.00990.x
Subject(s) - human leukocyte antigen , medicine , transplantation , immunology , hematopoietic stem cell transplantation , histocompatibility , minor histocompatibility antigen , cytotoxic t cell , incidence (geometry) , stem cell , histocompatibility testing , graft versus host disease , antigen , major histocompatibility complex , biology , in vitro , genetics , physics , optics
Summary Functional assays measuring alloreactivity of donor cells are desired to detect either cryptic epitopes inducing graft‐ vs .‐host disease (GvHD) after human leukocyte antigen (HLA)‐identical hematopoietic stem cell transplantation (HSCT) or permissible HLA mismatches. However, their value in predicting GvHD and survival is still limited. We determined the cytotoxic and helper T‐cell precursor (CTLp and HTLp) frequencies by limiting dilution analysis (LDA) in 40 unrelated recipient/donor combinations. The median observation period at the time of this writing was 4.44 years (range from 0.1 to 11.28). Better overall survival was observed in patients with rather low host‐specific CTLp and HTLp frequencies, whereas a trend toward high CTLp frequencies was seen in patients with higher incidence of acute GvHD, especially in patients mismatched in HLA‐C. CTLp and HTLp frequencies did not correlate with the incidence of chronic GvHD and relapse. In conclusion, we detected a trend toward better overall survival of patient/donor pairs with low CTLp and HTLp frequencies, however, recommend to use LDA as an additional tool for identifying the most suitable donor when more than one fully HLA‐matched stem cell donor is available.